GTBP - שווי פעילות לרווח לפני ריבית, מסים ופחת gtbiopharma.com

GT Biopharma, Inc. (GTBP) relies on the precision transport of biologics using cold chains, as confirmed by the EV/EBITDA chart, which stands at 0.00. The company minimizes risks by creating protein compounds to stimulate NK cells in leukemia cases. Simultaneously, the business is developing the TriKE line, which is currently undergoing clinical trials for the targeted destruction of malignant neoplasms.

Fundamental asset screening requires an accurate determination of business value, accounting for debt load and tax liabilities. The company's current EV/EBITDA ratio compares the total enterprise value with its operating profit before depreciation and amortization, making it possible to identify the market bottom. For GT Biopharma, Inc. (GTBP), this metric reflects the laboratory research stage, where the absence of a commercial product renders the indicator a measure of investment momentum.